Table 3.

Covariance analysis of duration of BoNTa efficacy

Model summary	R	R2	Adjusted R2	Standard error	Durbin–Watson
	0.449	0.2013	0.148	2,621,350	0.387

ANOVA	Sum of squares	Degrees of freedom	Mean squares	F	p value
Regression	283,77	11	2579,785	3754	< 0.001*
Residual	112,692,227	164	687,148
Total	141,069,858	175

	B	Standard error	Beta	t	p value
Doses	− 0.259	0.059	− 0.409	− 4.369	< 0.001*
Years of treatment	− 0.390	0.319	− 0.100	− 1.224	0.223
Age	0.299	0.158	0.159	1.895	0.060
Sex	− 1.261	4.357	− 0.022	− 0.289	0.773
IncobotulinumtoxinA	− 14.766	6.112	− 0.196	− 2.416	0.017*
AbobotulinumtoxinA	− 8.999	10.071	− 0.147	− 0.894	0.373
Cervical dystonia	34.674	10.334	0.530	3.355	< 0.001*
Hemifacial spasm	5.649	5.633	0.080	1.003	0.317
Oromandibular dystonia	30.590	13348	0.180	2292	0023*
Focal dystonia	32.156	12.226	0.327	2.630	0.009*
Sialorrhea	− 5.314	9.164	− 0.045	− 0.580	0.563

As a categorical, non-dichotomous variable, type of toxin was inserted in the statistical model as a dummy variable with onabotulinumtoxin-A as the reference level (thus not present in the table)

Likely, type of disease was inserted as a dummy variable with blepharospasm as the reference level (thus not present in the table)

BoNT botulinum toxin